Kenji Yasukawa, Astellas CEO (Akio Kon/Bloomberg via Getty Images)
January 20, 2023 11:09 AM ESTUpdated 01:53 PM
Cell/Gene Tx
FDA+

FDA lifts clin­i­cal hold on Astel­las’ Pompe gene ther­a­py

Lei Lei Wu

News Reporter

The FDA has lift­ed a clin­i­cal hold on Astel­las Phar­ma’s Pompe dis­ease gene ther­a­py tri­al, the Japan­ese com­pa­ny an­nounced Fri­day morn­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times